Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.52 |
| ▸ | HTR2C | P28335 | 9/20 | 0.52 |
| ▸ | HTR2B | P41595 | 9/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183306 | 0.89 | HTR2A (0.53) | HTR2AHTR2CHTR2B | |
| SCHEMBL183613 | 0.86 | PDE10A (0.44) | HTR2CPDE10AMTORPRKCIC5AR1 | |
| SCHEMBL184023 | 0.82 | HTR2A (0.51) | HTR2AHTR2CHTR2BPDE10AMTOR | |
| SCHEMBL194527 | 0.79 | PDE10A (0.40) | HTR2CPDE10AMTORPRKCIC5AR1 | |
| SCHEMBL14328064 | 0.78 | P2RX7 (0.49) | PDE10AMTORCKS1BSKP1SKP2 | |
| SCHEMBL1622444 | 0.78 | CNR1 (0.42) | HTR2AHTR2CHTR2BMTOR | |
| SCHEMBL1621309 | 0.77 | HTR2C (0.42) | HTR2AHTR2CPRKCI | |
| SCHEMBL27013367 | 0.77 | PARP1 (0.43) | MTORPRKCI | |
| SCHEMBL27013365 | 0.77 | P2RX3 (0.47) | MTORPRKCI | |
| SCHEMBL1261952 | 0.77 | PARP1 (0.42) | MTORPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618288-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | disclosed |
| US-7598255-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-06 | — | — | US | disclosed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | HTR2A 4/4885HTR2C 11/4885HTR2B 10/4885 |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | HTR2A 4/4885HTR2C 11/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.